AnaptysBio Inc (NAS:ANAB)
$ 23.91 -1.01 (-4.05%) Market Cap: 653.19 Mil Enterprise Value: 343.50 Mil PE Ratio: 0 PB Ratio: 13.66 GF Score: 60/100

AnaptysBio Inc at JPMorgan Healthcare Conference (Virtual) Transcript

Jan 14, 2021 / 02:10PM GMT
Release Date Price: $25.63 (+7.33%)
Anupam Rama
JPMorgan Chase & Co, Research Division - VP and Analyst

Welcome, everybody, to the 39th Annual JPMorgan Healthcare Conference. My name is Anupam Rama. I'm one of the senior biotech analysts here at JPMorgan. I'm joined by Matt Bannon and Tessa Romero from the team.

Our next presenting company is AnaptysBio. Presenting on behalf of the company, we have CEO, Hamza Suria.

(Operator Instructions)

With that, I'll turn it over to Hamza, Hamza?

Hamza Suria
AnaptysBio, Inc. - President, CEO & Director

Thank you so much, Anupam. Good morning, everyone, and thank you to the JPMorgan team for this opportunity to provide an overview of what 2021 involves for AnaptysBio. I will be making forward-looking statements during the course of the presentation. We refer you to our SEC filings for relevant risks and disclosures.

On Slide 3 is a summary regarding the company. AnaptysBio is a clinical stage antibody R&D engine focused on first-in-class immunology opportunities. Our strategy is to innovate novel

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot